{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:17:31Z","timestamp":1792052251121,"version":"4.4.0"},"reference-count":341,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","award":["TF-2020-03"],"award-info":[{"award-number":["TF-2020-03"]}],"id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ard.2025.08.021","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:10:15Z","timestamp":1756984215000},"page":"22-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)"],"prefix":"10.1016","volume":"85","author":[{"given":"Katerina M.","family":"Antoniou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Gheorghiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Vikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Bizymi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Galetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera J.","family":"Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venerino","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta A.","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Strek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sverzellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Studenic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibril","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blin","family":"Nagavci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomy","family":"Tonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.08.021_bib0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1378\/chest.10-0194","article-title":"Connective tissue disease-associated interstitial lung disease","volume":"138","author":"Fischer","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0002","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.reuma.2021.07.008","article-title":"Screening of interstitial lung disease in patients with rheumatoid arthritis: a systematic review","volume":"18","author":"Garrote-Corral","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ard.2025.08.021_bib0003","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00221-2018","article-title":"New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards","volume":"51","author":"Miravitlles","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ard.2025.08.021_bib0006","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.08.021_bib0007","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ard.2025.08.021_bib0008","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: Version 6.0","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ard.2025.08.021_bib0009","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ard.2025.08.021_bib0010","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.08.021_bib0011","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.08.021_bib0012","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/art.41415","article-title":"Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis","volume":"72","author":"Bernstein","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0013","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0014","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000335473","article-title":"Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide","volume":"84","author":"Pernot","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.ard.2025.08.021_bib0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00296-017-3916-x","article-title":"Interstitial lung disease in systemic sclerosis: data from the Spanish Scleroderma Study Group","volume":"38","author":"Sanchez-Cano","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.08.021_bib0017","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3899\/jrheum.171362","article-title":"Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis","volume":"45","author":"Showalter","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/03009742.2015.1011228","article-title":"Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography","volume":"44","author":"Sperandeo","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0019","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0020","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.58.10.635","article-title":"Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis","volume":"58","author":"Witt","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0021","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/thx.56.8.622","article-title":"Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests","volume":"56","author":"Dawson","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.ard.2025.08.021_bib0022","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0023","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-010-1492-5","article-title":"Pulmonary involvement in early rheumatoid arthritis patients","volume":"30","author":"Habib","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0024","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1756-185X.2009.01376.x","article-title":"Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease","volume":"12","author":"Mohd Noor","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0025","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/kes167","article-title":"Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort","volume":"51","author":"Chua","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ard.2003.006122","article-title":"Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis","volume":"63","author":"Fathi","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0027","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/03009740600844381","article-title":"Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography","volume":"35","author":"Afeltra","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-022-02786-x","article-title":"Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases","volume":"24","author":"Hoffmann","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.08.021_bib0029","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/annrheumdis-2011-201072","article-title":"Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis","volume":"72","author":"Barskova","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0030","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.3390\/jcm10184114","article-title":"Lung ultrasound in the screening of pulmonary interstitial involvement secondary to systemic connective tissue disease: a prospective pilot study involving 180 patients","volume":"10","author":"Buda","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0031","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5606\/ArchRheumatol.2016.5849","article-title":"Effectiveness of thoracic ultrasonography in the evaluation of the severity of pulmonary involvement in patients with systemic sclerosis","volume":"31","author":"\u00c7akir Edis","year":"2016","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0032","first-page":"156","article-title":"Transthoracic ultrasound in the detection of interstitial pulmonary fibrosis in patients with rheumatic connective tissue diseases","volume":"76","author":"Fehr","year":"2018","journal-title":"Bull Hosp Jt Dis (2013)"},{"key":"10.1016\/j.ard.2025.08.021_bib0033","doi-asserted-by":"crossref","first-page":"Si56","DOI":"10.1093\/rheumatology\/keab801","article-title":"Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening","volume":"61","author":"Gargani","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105407","article-title":"The emerging role of ultrasound in detecting interstitial lung disease in patients with rheumatoid arthritis","volume":"89","author":"Gutierrez","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ard.2025.08.021_bib0035","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/RHU.0000000000000860","article-title":"Lung ultrasound as a screening method for interstitial lung disease in patients with systemic sclerosis","volume":"25","author":"Hassan","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0036","first-page":"199","article-title":"Ultrasound screening for interstitial lung disease in rheumatoid arthritis","volume":"32","author":"Moazedi-Fuerst","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.11152\/mu.2014.2066.161.am1so2","article-title":"Comparison of a new, modified lung ultrasonography technique with high-resolution CT in the diagnosis of the alveolo-interstitial syndrome of systemic scleroderma","volume":"16","author":"Mohammadi","year":"2014","journal-title":"Med Ultrason"},{"key":"10.1016\/j.ard.2025.08.021_bib0038","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.reuma.2019.05.004","article-title":"Subclinical interstitial lung disease in patients with systemic sclerosis. A pilot study on the role of ultrasound","volume":"17","author":"Reyes-Long","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ard.2025.08.021_bib0039","doi-asserted-by":"crossref","first-page":"e0566","DOI":"10.1097\/MD.0000000000010566","article-title":"Ultrasound B-lines in the evaluation of interstitial lung disease in patients with systemic sclerosis: cut-off point definition for the presence of significant pulmonary fibrosis","volume":"97","author":"Tardella","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ard.2025.08.021_bib0040","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00296-017-3893-0","article-title":"Interstitial lung disease in South Africans with systemic sclerosis","volume":"38","author":"Ashmore","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.08.021_bib0041","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00296-018-3987-3","article-title":"Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease","volume":"38","author":"Benyamine","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.08.021_bib0042","doi-asserted-by":"crossref","first-page":"9468","DOI":"10.1038\/s41598-019-45990-7","article-title":"Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis","volume":"9","author":"Bocchino","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2025.08.021_bib0043","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/RHU.0000000000000815","article-title":"Nailfold videocapillaroscopy changes are associated with the presence and severity of systemic sclerosis-related interstitial lung disease","volume":"25","author":"Caetano","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0044","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1756-185X.13452","article-title":"Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort","volume":"22","author":"Cao","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13075-018-1775-9","article-title":"Quantitative videocapillaroscopy correlates with functional respiratory parameters: a clue for vasculopathy as a pathogenic mechanism for lung injury in systemic sclerosis","volume":"20","author":"Guillen-Del-Castillo","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.08.021_bib0046","first-page":"657","article-title":"Study of the correlation between HRCT semi-quantitative scoring, concentration of alveolar nitric oxide, and clinical-functional parameters of systemic sclerosis-induced interstitial lung disease","volume":"93","author":"Hoang-Duc","year":"2020","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0047","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/acr.20336","article-title":"Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry","volume":"63","author":"Khimdas","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.08.021_bib0048","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.ard.2025.08.021_bib0049","first-page":"1081","article-title":"Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies","volume":"56","author":"Markusse","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-019-1919-6","article-title":"Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study","volume":"21","author":"Matsuda","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.08.021_bib0051","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13075-019-2057-x","article-title":"Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide","volume":"21","author":"Mitev","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.08.021_bib0052","doi-asserted-by":"crossref","first-page":"e8980","DOI":"10.1097\/MD.0000000000008980","article-title":"Clinical and serological features of systemic sclerosis in a multicenter African American cohort: analysis of the genome research in African American scleroderma patients clinical database","volume":"96","author":"Morgan","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ard.2025.08.021_bib0053","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0054","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/resp.13988","article-title":"Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression","volume":"26","author":"Stock","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2025.08.021_bib0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10067-021-05918-x","article-title":"Association of quantitative computed tomography indices with lung function and extent of pulmonary fibrosis in patients with systemic sclerosis","volume":"41","author":"Temiz Karadag","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0056","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2397198319869564","article-title":"Prediction of organ involvement and survival in systemic sclerosis patients in the first 5\u2005years from diagnosis","volume":"5","author":"van den Hombergh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.ard.2025.08.021_bib0057","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1007\/s10067-020-05105-4","article-title":"Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment","volume":"39","author":"Vanaken","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0058","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.semarthrit.2021.07.018","article-title":"Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in Flanders: a retrospective cohort study","volume":"51","author":"Vandecasteele","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0059","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0060","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0061","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl. 106","key":"10.1016\/j.ard.2025.08.021_bib0062","first-page":"98","article-title":"Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis","volume":"35","author":"Iniesta Arandia","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0063","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archinternmed.2007.59","article-title":"Progressive preclinical interstitial lung disease in rheumatoid arthritis","volume":"168","author":"Gochuico","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0064","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/406927","article-title":"Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease","volume":"2013","author":"Chen","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.ard.2025.08.021_bib0065","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/cells9030691","article-title":"Anti-HLA class II antibodies correlate with C-reactive protein levels in patients with rheumatoid arthritis associated with interstitial lung disease","volume":"9","author":"Del Angel-Pablo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ard.2025.08.021_bib0066","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1378\/chest.13-1394","article-title":"Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis","volume":"146","author":"Doyle","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0067","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s10067-021-05585-y","article-title":"Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease","volume":"40","author":"Fotoh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0068","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/annrheumdis-2012-203160","article-title":"Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease","volume":"73","author":"Giles","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0069","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3109\/03009748609098205","article-title":"Diffuse interstitial lung disease in rheumatoid arthritis. Views on immunological and HLA findings","volume":"15","author":"Hakala","year":"1986","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0070","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0071","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","article-title":"Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort","volume":"49","author":"Koduri","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0072","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10067-019-04846-1","article-title":"A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"39","author":"Li","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0073","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s10067-021-05655-1","article-title":"Utility of pulmonary ultrasound to identify interstitial lung disease in patients with rheumatoid arthritis","volume":"40","author":"Mena-Vazquez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0074","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.reuma.2019.06.001","article-title":"Analysis of clinical\u2013analytical characteristics in patients with rheumatoid arthritis and interstitial lung disease: case\u2013control study","volume":"17","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ard.2025.08.021_bib0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017088","article-title":"High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities","volume":"98","author":"Salaffi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ard.2025.08.021_bib0076","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5606\/ArchRheumatol.2018.6691","article-title":"Tumor-associated antigens in rheumatoid arthritis interstitial lung disease or malignancy?","volume":"33","author":"Sargin","year":"2018","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105948","article-title":"Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study","volume":"166","author":"Wu","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0078","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0079","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.08.021_bib0080","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.semarthrit.2021.04.012","article-title":"The phenotype of myositis patients with anti-Ku autoantibodies","volume":"51","author":"Casal-Dominguez","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0081","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/648570","article-title":"A clinical analysis of risk factors for interstitial lung disease in patients with idiopathic inflammatory myopathy","volume":"2013","author":"Cen","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.ard.2025.08.021_bib0082","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3349\/ymj.2021.62.5.424","article-title":"Comparison of the 2017 EULAR\/ACR criteria with clinicoserologic criteria for the classification of idiopathic inflammatory myopathies in Korean patients","volume":"62","author":"Chung","year":"2021","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ard.2025.08.021_bib0083","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12890-021-01802-1","article-title":"Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies","volume":"22","author":"Ge","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0084","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3346\/jkms.2016.31.3.389","article-title":"Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a Korean retrospective cohort study","volume":"31","author":"Go","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ard.2025.08.021_bib0085","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s10067-019-04501-9","article-title":"Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis","volume":"38","author":"Hu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0086","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s10072-020-04911-7","article-title":"The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease","volume":"42","author":"Huang","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ard.2025.08.021_bib0087","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0088","first-page":"1012","article-title":"Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis","volume":"34","author":"Matsushita","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0089","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.08.021_bib0090","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00296-012-2545-7","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients","volume":"33","author":"Sun","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.08.021_bib0091","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12016-020-08814-5","article-title":"Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis","volume":"60","author":"Vojinovic","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ard.2025.08.021_bib0092","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s10067-022-06089-z","article-title":"Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0094","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ard.2025.08.021_bib0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.08.021_bib0096","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jocn.2020.01.060","article-title":"Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy","volume":"74","author":"Huang","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ard.2025.08.021_bib0097","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.08.021_bib0098","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/keh575","article-title":"Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD)","volume":"44","author":"Bodolay","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0099","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","article-title":"Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease","volume":"55","author":"Gunnarsson","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105895","article-title":"Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjogren syndrome","volume":"163","author":"Buvry","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0101","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s10067-018-4289-6","article-title":"A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjogren's syndrome-related interstitial lung disease in a Chinese population","volume":"37","author":"Dong","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0102","article-title":"Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjogren syndrome patients: a case-control study","volume":"97","author":"Gao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ard.2025.08.021_bib0103","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1080\/07853890.2021.1965205","article-title":"Clinical profiles of SS-ILD compared with SS-NILD in a Chinese population: a retrospective analysis of 735 patients","volume":"53","author":"Guo","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0104","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/1756-185X.13881","article-title":"Prevalence and risk factors of interstitial lung disease in patients with primary Sjogren's syndrome: a systematic review and meta-analysis","volume":"23","author":"He","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12890-022-01868-5","article-title":"Interstitial lung disease in primary Sjogren's syndrome","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","article-title":"Interstitial lung disease in primary Sjogren's syndrome","volume":"16","author":"Roca","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2025.08.021_bib0107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fmed.2020.00332","article-title":"Lung involvement in primary Sjogren's syndrome-an under-diagnosed entity","volume":"7","author":"Sogkas","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.021_bib0108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1590\/abd1806-4841.20175476","article-title":"Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus","volume":"92","author":"Su","year":"2017","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0109","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.resinv.2019.04.005","article-title":"Clinical features of interstitial pneumonia associated with systemic lupus erythematosus","volume":"57","author":"Toyoda","year":"2019","journal-title":"Respir Investig"},{"key":"10.1016\/j.ard.2025.08.021_bib0110","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.semarthrit.2020.02.015","article-title":"Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: description and prognosis factors","volume":"50","author":"Forestier","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0111","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0112","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0113","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0114","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chest.2022.09.044","article-title":"Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European scleroderma trials and research","volume":"163","author":"Hoffmann-Vold","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Le Gouellec","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ard.2025.08.021_bib0116","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0117","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.15-0003","article-title":"Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis","volume":"148","author":"Ryerson","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0118","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0119","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/resp.13309","article-title":"Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease","volume":"23","author":"Winstone","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2025.08.021_bib0120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0121","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/resp.13175","article-title":"Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease","volume":"23","author":"Takei","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2025.08.021_bib0122","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1038\/s41598-021-88734-2","article-title":"Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis","volume":"11","author":"Cano-Jim\u00e9nez","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2025.08.021_bib0123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000502551","article-title":"Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality","volume":"98","author":"Hyldgaard","year":"2019","journal-title":"Respiration"},{"key":"10.1016\/j.ard.2025.08.021_bib0124","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00092309","article-title":"Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Kim","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0125","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/resp.13848","article-title":"Risk prediction model in rheumatoid arthritis-associated interstitial lung disease","volume":"25","author":"Kim","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2025.08.021_bib0126","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0127","first-page":"344","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Zamora-Legoff","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0128","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1093\/rheumatology\/keac208","article-title":"The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease","volume":"61","author":"Brooks","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0129","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s10067-021-06040-8","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis","volume":"41","author":"Rojas-Serrano","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0130","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0131","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1093\/rheumatology\/kead027","article-title":"Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease","volume":"62","author":"Chang","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152004","article-title":"Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options","volume":"55","author":"Chen","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0133","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.chest.2020.04.061","article-title":"Baseline characteristics and progression of a spectrum of interstitial lung abnormalities and disease in rheumatoid arthritis","volume":"158","author":"Kawano-Dourado","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0134","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/mr\/roac115","article-title":"Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: an ANSWER cohort study","volume":"33","author":"Makino","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4078\/jrd.2021.28.4.234","article-title":"Association of serum biomarkers with pulmonary involvement of rheumatoid arthritis interstitial lung disease: from KORAIL cohort baseline data","volume":"28","author":"Moon","year":"2021","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0136","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/151626","article-title":"Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis","volume":"2015","author":"Rocha-Mu\u00f1oz","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0137","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis","volume":"36","author":"Rojas-Serrano","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0138","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1080\/14397595.2021.1879346","article-title":"Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0139","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/rheumatology\/38.7.668","article-title":"Extra-articular rheumatoid arthritis: prevalence and mortality","volume":"38","author":"Turesson","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0140","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0141","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003491","article-title":"Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database","volume":"9","author":"Juge","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.08.021_bib0142","doi-asserted-by":"crossref","first-page":"SI286","DOI":"10.1093\/rheumatology\/kead277","article-title":"Rheumatoid arthritis, quantitative parenchymal lung features, and mortality among smokers","volume":"62","author":"McDermott","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0143","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0144","article-title":"Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease","volume":"15","author":"Kim","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ard.2025.08.021_bib0145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152187","article-title":"Survival of adults with rheumatoid arthritis associated interstitial lung disease \u2013 a systematic review and meta-analysis","volume":"60","author":"Farquhar","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0147","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","article-title":"Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients","volume":"28","author":"Fujiki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0148","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0149","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"61","author":"Gui","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0150","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.rmed.2014.09.003","article-title":"Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type","volume":"108","author":"Johnson","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0151","article-title":"Clinical features and outcomes of patients with myositis associated-interstitial lung disease","volume":"9","author":"Karampitsakos","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.021_bib0152","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/14397595.2015.1134392","article-title":"Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"26","author":"Kotani","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0153","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0154","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0156","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.021_bib0157","article-title":"A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis","volume":"11","author":"Xu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2025.08.021_bib0158","article-title":"A computed tomography radiomics-based prediction model on interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.021_bib0159","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10067-021-06033-7","article-title":"Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study","volume":"41","author":"Yamaguchi","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0160","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22978","article-title":"Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease","volume":"33","author":"Ye","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.ard.2025.08.021_bib0161","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.resinv.2016.08.007","article-title":"Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"55","author":"Yoshida","year":"2017","journal-title":"Respir Investig"},{"key":"10.1016\/j.ard.2025.08.021_bib0162","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/mr\/roab017","article-title":"Clinical significance of HScore and MS score comparison in the prognostic evaluation of anti-MDA5-positive patients with dermatomyositis and interstitial lung disease","volume":"32","author":"Zhao","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0163","doi-asserted-by":"crossref","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","article-title":"Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease","volume":"40","author":"Zhu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0164","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","article-title":"HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients","volume":"34","author":"Zou","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.08.021_bib0166","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0167","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72752-7","article-title":"The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease","volume":"10","author":"Wakura","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2025.08.021_bib0168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073774","article-title":"Prognostic factors in interstitial lung disease associated with primary Sj\u00f6gren's syndrome: a retrospective analysis of 33 pathologically-proven cases","volume":"8","author":"Enomoto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ard.2025.08.021_bib0169","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00330-003-2026-1","article-title":"Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis","volume":"14","author":"Biederer","year":"2004","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ard.2025.08.021_bib0170","first-page":"349","article-title":"Relationship between abnormalities on high-resolution computerized tomography, pulmonary function, and bronchoalveolar lavage in progressive systemic sclerosis","volume":"33","author":"Cakmak","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0171","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1497","article-title":"Mast cells\u2019 contribution to the fibrosing alveolitis of the scleroderma lung","volume":"147","author":"Chanez","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0172","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1465-9921-6-96","article-title":"Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis","volume":"6","author":"De Santis","year":"2005","journal-title":"Respir Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0173","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","article-title":"Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease","volume":"6","author":"De Santis","year":"2012","journal-title":"Clin Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0174","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/art.22696","article-title":"Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression","volume":"56","author":"Goh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0175","first-page":"22","article-title":"Assessments of pulmonary involvement in patients with systemic sclerosis","volume":"14","author":"Gohari Moghadam","year":"2011","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0176","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/keab586","article-title":"Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease","volume":"61","author":"He","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0177","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-015-0154-4","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?","volume":"15","author":"Ikeda","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0178","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.21037\/jtd-20-2596","article-title":"Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease","volume":"13","author":"Kase","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0179","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/art.11042","article-title":"Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease","volume":"48","author":"Kowal-Bielecka","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0180","first-page":"765","article-title":"Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis","volume":"27","author":"Meloni","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0181","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3390\/microorganisms9050932","article-title":"The role of lung colonization in connective tissue disease-associated interstitial lung disease","volume":"9","author":"Ricci","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ard.2025.08.021_bib0182","first-page":"35","article-title":"The differing patterns of subclinical pulmonary involvement in connective tissue diseases as shown by application of factor analysis","volume":"19","author":"Salaffi","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0183","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/37.3.263","article-title":"A longitudinal study of pulmonary involvement in primary Sj\u00f6gren's syndrome: relationship between alveolitis and subsequent lung changes on high-resolution computed tomography","volume":"37","author":"Salaffi","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0184","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar2766","article-title":"Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients","volume":"11","author":"Schmidt","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.08.021_bib0185","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00296-010-1390-9","article-title":"Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters","volume":"31","author":"Volpinari","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.08.021_bib0186","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/art.20265","article-title":"Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis","volume":"50","author":"Clements","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0187","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/crj.12318","article-title":"The evaluation of clinical usefulness of transbrochoscopic lung biopsy in undefined interstitial lung diseases: a retrospective study","volume":"11","author":"Han","year":"2017","journal-title":"Clin Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0188","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1378\/chest.130.5.1489","article-title":"Interstitial lung disease in primary Sj\u00f6gren syndrome","volume":"130","author":"Parambil","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0189","doi-asserted-by":"crossref","first-page":"e8513","DOI":"10.1590\/1414-431x20198513","article-title":"Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension","volume":"52","author":"Andrade","year":"2019","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0190","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/rheumatology\/kel221","article-title":"Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis","volume":"46","author":"Beretta","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0191","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard.2006.054866","article-title":"Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test","volume":"66","author":"Buch","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0192","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12890-019-0943-2","article-title":"Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study","volume":"19","author":"Chan","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0193","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3899\/jrheum.080447","article-title":"Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma","volume":"36","author":"Garin","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0194","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.08.021_bib0195","first-page":"S142","article-title":"Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease","volume":"33","author":"Rizzi","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0196","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4187\/respcare.02452","article-title":"Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease","volume":"59","author":"Someya","year":"2014","journal-title":"Respir Care"},{"key":"10.1016\/j.ard.2025.08.021_bib0197","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijcard.2016.03.084","article-title":"Six-minute walk test in systemic sclerosis: a systematic review and meta-analysis","volume":"212","author":"Vandecasteele","year":"2016","journal-title":"Int J Cardiol"},{"issue":"Suppl. 106","key":"10.1016\/j.ard.2025.08.021_bib0198","first-page":"122","article-title":"Six-minute walk test in or out in evaluation of systemic sclerosis patients?","volume":"35","author":"Vandecasteele","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0199","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1440-1843.2012.02133.x","article-title":"The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease","volume":"17","author":"Wilsher","year":"2012","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2025.08.021_bib0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.chest.2022.01.007","article-title":"Acute respiratory deterioration in rheumatoid arthritis-associated interstitial lung disease: a single-center study","volume":"162","author":"Kwon","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0201","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3899\/jrheum.151067","article-title":"Pulmonary involvement in the antisynthetase syndrome: a comparative cross-sectional study","volume":"43","author":"Andersson","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0202","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00296-018-4050-0","article-title":"Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies","volume":"38","author":"Mugii","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.08.021_bib0203","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1136\/annrheumdis-2011-201253","article-title":"Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study","volume":"71","author":"Gunnarsson","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0204","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.778649","article-title":"Autoimmune progressive fibrosing interstitial lung disease: predictors of fast decline","volume":"12","author":"Nagy","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ard.2025.08.021_bib0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000598","article-title":"ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF","volume":"7","author":"Durheim","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0206","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0207","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/rheumatology\/kep284","article-title":"Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial \u2013 results from the Scleroderma Lung Study","volume":"48","author":"Khanna","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0208","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0209","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/rheumatology\/keu456","article-title":"Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis","volume":"54","author":"Wallace","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0210","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0211","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"issue":"Suppl. B","key":"10.1016\/j.ard.2025.08.021_bib0212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George's Respiratory Questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0213","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire","volume":"8","author":"Webster","year":"1999","journal-title":"Quality of Life Research"},{"key":"10.1016\/j.ard.2025.08.021_bib0214","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1164\/ajrccm.159.1.ats898","article-title":"Mechanisms, assessment, and management: a consensus statement. American Thoracic Society","volume":"159","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0215","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","article-title":"The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire","volume":"67","author":"Patel","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.ard.2025.08.021_bib0216","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0217","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0218","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/resp.13293","article-title":"Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease","volume":"23","author":"Suzuki","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2025.08.021_bib0219","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2021-001167","article-title":"Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases","volume":"9","author":"Swigris","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0220","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1007\/s10067-021-05693-9","article-title":"Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability","volume":"40","author":"Topcu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0221","first-page":"A5353","article-title":"Living with idiopathic pulmonary fibrosis (L-IPF): developing a patient-reported symptom and impact questionnaire to assess health-related quality of life in IPF","volume":"195","author":"Graney","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0222","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1600-0838.2009.00985.x","article-title":"An index for breathlessness and leg fatigue","volume":"20","author":"Borg","year":"2010","journal-title":"Scand J Med Sci Sports"},{"key":"10.1016\/j.ard.2025.08.021_bib0223","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10067-020-05375-y","article-title":"Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests","volume":"40","author":"Carnevale","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0224","article-title":"Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: a cohort study","volume":"10","author":"Chiu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.021_bib0225","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00004728-200109000-00015","article-title":"Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation","volume":"25","author":"Kim","year":"2001","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.ard.2025.08.021_bib0226","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.chest.2021.11.033","article-title":"Early radiographic progression of scleroderma: lung disease predicts long-term mortality","volume":"161","author":"Volkmann","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0227","doi-asserted-by":"crossref","first-page":"381","DOI":"10.21037\/qims.2016.08.08","article-title":"Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients","volume":"6","author":"Wangkaew","year":"2016","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.ard.2025.08.021_bib0228","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.08.021_bib0229","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0230","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ard.2025.08.021_bib0231","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the Scleroderma Lung Study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0232","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0233","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00330-011-2223-2","article-title":"Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide","volume":"21","author":"Kim","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ard.2025.08.021_bib0234","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/annrheumdis-2015-208929","article-title":"Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment","volume":"75","author":"Kim","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0235","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02182-2018","article-title":"Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease","volume":"53","author":"Jhajj","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0236","doi-asserted-by":"crossref","first-page":"SI32","DOI":"10.1093\/rheumatology\/keac319","article-title":"Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation","volume":"62","author":"Pugnet","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0237","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4172\/2161-1149.1000154","article-title":"Development of a composite outcome measure for systemic sclerosis related interstitial lung disease","volume":"5","author":"Volkmann","year":"2015","journal-title":"Rheumatology (Sunnyvale)"},{"key":"10.1016\/j.ard.2025.08.021_bib0238","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.41085","article-title":"Using transitional changes on high-resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis-related interstitial lung disease","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0239","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON","volume":"81","author":"Allanore","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0240","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4046\/trd.2020.0043","article-title":"Short-term lung function changes and predictors of progressive systemic sclerosis-related interstitial lung disease","volume":"83","author":"Kaenmuang","year":"2020","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.ard.2025.08.021_bib0241","first-page":"S111","article-title":"Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease","volume":"33","author":"Moore","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0242","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0243","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0244","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases \u2013 subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0245","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/keac535","article-title":"Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial","volume":"62","author":"Denton","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0246","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0247","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0248","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.08.021_bib0249","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13075-015-0872-2","article-title":"Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials","volume":"17","author":"Khanna","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.08.021_bib0250","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression","volume":"9","author":"Khanna","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.08.021_bib0251","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0252","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.08.021_bib0253","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-022-02095-6","article-title":"Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects","volume":"23","author":"Maher","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.ard.2025.08.021_bib0254","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","article-title":"Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling","volume":"54","author":"Man","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0255","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2\u2005years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0256","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0257","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ard.2025.08.021_bib0258","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0259","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0260","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0261","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/jcm10040874","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","volume":"10","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0262","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00408-019-00276-7","article-title":"Clinical characteristics and natural history of autoimmune forms of interstitial lung disease: a single-center experience","volume":"197","author":"Chartrand","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.ard.2025.08.021_bib0263","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/rheumatology\/keac651","article-title":"Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0264","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0265","article-title":"Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease","volume":"39","author":"Sahin Eroglu","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0266","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.semarthrit.2021.07.002","article-title":"MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression","volume":"51","author":"Juge","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0267","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0268","article-title":"The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.021_bib0269","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0270","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01641-2018","article-title":"Telomere length and genetic variant associations with interstitial lung disease progression and survival","volume":"53","author":"Newton","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0271","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ard.2025.08.021_bib0272","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0273","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.23571","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology","volume":"59","author":"Fathi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0274","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2025.08.021_bib0275","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0276","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2025.08.021_bib0277","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0278","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0279","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0280","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0281","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0282","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1346-8138.15274","article-title":"Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"47","author":"Matsuda","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0283","first-page":"136","article-title":"Treatment of primary Sj\u00f6gren's syndrome-related interstitial lung disease: a retrospective cohort study","volume":"37","author":"Amlani","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0284","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ard.2025.08.021_bib0285","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.021_bib0286","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-021-01705-8","article-title":"Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients","volume":"16","author":"Yang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0287","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.08.021_bib0288","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.08.021_bib0289","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease","volume":"151","author":"Tashkin","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.ard.2025.08.021_bib0290","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II","volume":"2","author":"Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0291","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0292","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","volume":"8","author":"Kuster","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.08.021_bib0293","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0294","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis- interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0295","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0296","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0297","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"issue":"Suppl. 71","key":"10.1016\/j.ard.2025.08.021_bib0298","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0299","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.08.021_bib0300","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0301","first-page":"838","article-title":"Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease","volume":"20","author":"Silver","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0302","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0303","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0304","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0305","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study","volume":"47","author":"Langlois","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0306","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin A and 2-hour post-dose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis","volume":"35","author":"Kotani","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0307","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0308","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0309","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"IC","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0310","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0311","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00163911","article-title":"Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy","volume":"40","author":"Keir","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0312","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.ard.2025.08.021_bib0313","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ard.2025.08.021_bib0314","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10067-018-4382-x","article-title":"Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population","volume":"38","author":"Fu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0315","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","article-title":"Rheumatoid arthritis related interstitial lung disease \u2013 improving outcomes over 25 years: a large multicentre UK study","volume":"60","author":"Kelly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0316","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000473","article-title":"Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic","volume":"3","author":"Druce","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.08.021_bib0317","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/jcm9041082","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0318","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.ard.2025.08.021_bib0319","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ard.2025.08.021_bib0320","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/rheumatology\/keab317","article-title":"Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis \u2013 multicentre study of 263 Caucasian patients","volume":"61","author":"Fern\u00e1ndez-D\u00edaz","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0321","article-title":"Cyclophosphamide for rheumatoid arthritis","volume":"2000","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ard.2025.08.021_bib0322","article-title":"Azathioprine for treating rheumatoid arthritis","volume":"2000","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ard.2025.08.021_bib0323","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ard.2025.08.021_bib0324","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review","volume":"20","author":"Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2025.08.021_bib0325","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s10067-016-3357-z","article-title":"Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Zamora-Legoff","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0326","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"issue":"Suppl. 100","key":"10.1016\/j.ard.2025.08.021_bib0327","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0328","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0329","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/acr2.11210","article-title":"Rituximab versus mycophenolate in the treatment of recalcitrant connective tissue disease-associated interstitial lung disease","volume":"3","author":"Zhu","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0330","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1093\/rheumatology\/keac091","article-title":"Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial","volume":"61","author":"Volkmann","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.08.021_bib0331","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100\u2009weeks: data from a randomized controlled trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0332","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2665-9913(22)00215-6","article-title":"Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials","volume":"4","author":"Hoffmann-Vold","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.08.021_bib0333","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial","volume":"79","author":"Seibold","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0334","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0335","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2025.08.021_bib0336","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0337","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0338","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0339","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/a-2017-8971","article-title":"Leitlinie Interdisziplin\u00e4re Diagnostik interstitieller Lungenerkrankungen im Erwachsenenalter [Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases]","volume":"77","author":"Kreuter","year":"2023","journal-title":"Pneumologie"},{"key":"10.1016\/j.ard.2025.08.021_bib0340","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"83","author":"Parodis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.021_bib0341","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003350","article-title":"Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases","volume":"9","author":"Santos","year":"2023","journal-title":"RMD Open"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:21:58Z","timestamp":1768314118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725043201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":341,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0003496725043201"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.021","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}